

Special Issue

Diagnosis, Treatment, and Survivorship of Lymphoma in the Era of Personalized Medicine

Message from the Guest Editor

Personalized medicine offers the possibility of identifying HL patients that can be cured with less toxic regimens in an effort to minimize adverse effects and improve patient quality of life. With recent advances such as next-generation sequencing (NGS), personalized medicine offers opportunities to diagnose NHL patients earlier, tailor treatment based on genomic or molecular alterations, minimize adverse effects, and detect relapsed disease sooner. This Special Issue of the Journal of Personalized Medicine aims to highlight the recent developments in personalized approaches to the diagnosis, treatment, and survivorship of lymphoma patients. Articles or comprehensive reviews on the identification and characterization of novel biomarkers for disease diagnosis, therapy selection, and monitoring, as well as those that describe new methods and approaches used for these purposes, are welcome.

Guest Editor

Dr. Andrew Ip

Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA

Deadline for manuscript submissions

closed (20 January 2026)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/237883

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).